Image

Europe Transplant Diagnostics Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • Nov 2022
  • Europe
  • 350 Pages
  • No of Tables: 421
  • No of Figures: 43
  • Medical Devices
  • Published Report
  • Nov 2022
  • Europe
  • 350 Pages
  • No of Tables: 421
  • No of Figures: 43

Europe Transplant Diagnostics Market, By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other Transplants), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales and Others) Industry Trends and Forecast to 2029.

Europe Transplant Diagnostics Market

Europe Transplant Diagnostics Market Analysis and Insights

Transplant diagnosis is a diagnostic procedure usually divided into pre-transplant and post-transplant procedures. It helps to analyze the health status of the patient. If this is avoided, the immunocompromised person is at risk of developing HAI or worse, which can lead to death. The procedure is a harmonious collaboration between healthcare professionals and laboratory experts, ensuring better patient outcomes. In addition, close matching of donor and recipient HLA markers is important. This increases the likelihood of graft survival and minimizes serious complications of immunological transplantation. The increased prevalence of chronic illnesses among the worldwide population is likely to drive market expansion throughout the forecast years. Furthermore, the increasing use of stem cell therapy and personalized medications is gaining popularity. The use of new diagnostic techniques has improved the medical outcomes of organ transplants. The rate of organ rejection can be reduced by matching the compatibility of the donor and recipient before transplantation.

Europe Transplant Diagnostics Market

Europe Transplant Diagnostics Market

However, the high cost of procedures associated with PCR and NGS diagnostic instruments is one of the most significant. As a result, market growth may be hampered in the long run. The cost of medical equipment is one element that may challenge critical transplant diagnosis device vendors.

Data Bridge Market Research analyzes that the Europe transplant diagnostics market is expected to reach a value of USD 2,933.94 million by 2029, at a CAGR of 6.2% during the forecast period. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019-2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales and Others)

Countries Covered

Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and the rest of Europe

Market Players Covered

Hologic, Inc., Biofortuna Limited, Takara Bio Inc., BAG Diagnostics GmbH, Abbott, Diagnóstica Longwood SL, Adaptive Biotechnologies, NanoString, Arquer Diagnostics Ltd, CLONIT srl, Biotype GmbH, PathoNostics, altona Diagnostics GmbH, ELITechGroup, DiaSorin S.p.A., Horiba Ltd, Laboratory Corporation of America Holdings., Randox Laboratories Ltd., TransMedics, Thermo Fisher Scientific Inc., Stryker, Bio-Rad Laboratories, Inc., Zimmer Biomet, QIAGEN, F. Hoffmann-La Roche Ltd, BIOMÉRIEUX, CareDx Inc., Illumina, Inc., Luminex Corporation (A subsidiary of DiaSorin Company), IMMUCOR, among others

Market Definition

Transplant diagnostics are the immunogenetics and histocompatibility of organ and hematopoietic stem cell transplantations. These diagnostics help healthcare professionals determine compatibility between potential recipients and organ donors. These are used in various disciplines, such as immunogenetics, pathology and infectious diseases, among others. Transplant diagnostics are used to determine whether the donor and the recipient of the organ are compatible before or after the transplant. With the introduction of transplant diagnostics, the prevalence of diseases that can cause organ failure, including both pre-and post-transplant screening, is expected to explode. The market has attracted the interest of healthcare professionals due to the many advantages these tests offer to verify suitability for a transplant procedure. Organ transplantation is one of the most popular treatment options for many end-stage renal disease patients on continuous dialysis.

In addition, it is possible to investigate organ transplantation for cases involving the heart, liver, or bone marrow. Although in many cases, there is a strong association between renal failure and liver transplantation, including end-stage renal disease. New transcriptomic, proteomic and genomic indicators in molecular diagnostics can help to better tailor transplant therapy and early detection of rejection events. Also, strategic initiatives by market players, technological progressions in transplant diagnostics, high sterility assurance and increasing investment in healthcare infrastructure increase the demand for transplant diagnostics.

Europe Transplant Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Rising number of transplant procedures

The demand for organ transplantation has rapidly increased worldwide during the past decade due to the increased incidence of vital organ failure and improved post-transplant outcomes. Demand for kidney, heart, liver and lungs transplant is very high. Alcohol consumption, lack of exercise and drug abuse are leading causes of organ failure. The number of living donor transplants has been affected by the COVID-19 pandemic. But living donor transplants have increased by 14.2 percent over 2020.

In addition, organ transplantation improves patient survival and quality of life and has a major positive impact on public health and the socioeconomic burden of organ failure. The European Union (EU) has a relatively uniform and structured approach to organ transplantation, well-developed national programs, international systems to facilitate organ sharing and well-defined exchange policies, making Europe a leader in this field.

Thus, the increasing number of transplant procedures across the globe and the increase in successful transplantations is expected to boost the Europe transplant diagnostics market.

  •  Increase in the technological advancements in the field of transplants

New technologies are rapidly changing traditional approaches to organ transplantation. The main challenges in organ transplantation are how best to identify and, if possible, eliminate the need for lifelong immunosuppression and how to expand the pool of donors suitable for human transplantation. Researchers have developed an advanced system where transport time can be extended by tricking donor organs into thinking they are still inside the body. This system keeps oxygenated blood flowing through the organs to delay tissue death. A normothermic perfusion machine mimics the human body, ensuring constant blood flow to the organ. The machine can also deliver drugs or other nutrients to keep the liver in optimal condition before the transplant.

In addition, bio-artificial organ production techniques are a range of enabling techniques that can be used to produce human organs based on bionic principles. Over the past ten years, significant progress has been made in developing various organ manufacturing technologies. The past decade has seen tremendous advances in new technologies such as single-cell RNA sequencing, Nano biotechnology and CRISPR-Cas9 gene editing. However, creative applications of such new and powerful technologies to improve clinical transplantation have only begun. With such tools, there are now good opportunities to make major breakthroughs in defining and providing optimized and individualized care for all organ transplants.

Restraint

  • High cost of organ transplantation

Organ transplantation therapy employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing players. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Also, organ transplants are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation and expensive medications.

In addition, desensitizing therapies have also been used to achieve transplantation from an incompatible donor. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.

Thus, the high cost of transplantation and treatment using advanced modalities and technology products will act as a major restraining factor for the growth of the Europe transplant diagnostics market.

Opportunity

  • Strategic initiatives by market players

The rise in the Europe transplant diagnostics market increases the need for strategic business ideas. It includes a partnership, business expansion and other development. The surge in demand for a donor organs is significantly increasing the demand for transplant diagnostic kits. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

These strategic initiatives, such as product launches, agreements and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the Europe transplant diagnostics market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may be expected to as an opportunity that helps them to drive the Europe transplant diagnostics market.

Challenge

  • Ethical challenges faced during organ transplantation

The surge in the incidence of failure of vital organs and inadequate supply of organs has created a wide gap between organ supply and organ demand. The issue has resulted in long approval times to receive an organ and a rise in deaths. The events, which occurred in the previous years and continue in the present, have raised many ethical, moral and societal issues regarding supply, the methods of organ allocation and the use of living donors as volunteers, including minors.

Lack of accuracy in reporting, the donated organs can't be supplied and procedures that neither relieve suffering nor prolong life are rapidly identified.

Issues such as lack of organ procurement, religious acceptance, brain death and misconceptions related to organ donation and transplantation are still present on many ethical personal and community levels, even within the medical community. The various aspects of ethical, cultural and religious nature should not be a barrier to the act of organ donation and transplantation all of these are issues to be solved. Therefore, ethical challenges faced during organ transplantation are expected to challenge market growth.

Post-COVID-19 Impact on Europe Transplant Diagnostics Market

Europe transplant diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the Europe transplant diagnostics market.

Recent Developments

  • In August 2022, QIAGEN announced the publication in the Journal of Molecular Pathology of an externally facilitated clinical NGS interpretation validation study, demonstrating that its clinical decision support software, QIAGEN Clinical Insight Interpret One (QCI Interpret One), achieved a higher level of concordance with a panel of experts than human reviewers achieved amongst each other. The study commissioned by QDI and carried out independently by Genomics Quality Assessment (GenQA) investigated the classification of variants reported from oncology patient samples. This has helped company to validate its research
  • In January 2022, Hoffmann-La Roche Ltd introduced Cobas Infinity edge, a cloud-based point-of-care platform accessible. With its advanced technology, healthcare practitioners can handle patient data. This has helped the company to diversify their product line

Europe Transplant Diagnostics Market Scope

Europe transplant diagnostics market is segmented into product type, technology, transplant type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Product Type

  • Transplant Diagnostic Instrument
  • Transplant Diagnostic Software
  • Transplant Diagnostic Reagent

On the basis of product type, the Europe transplant diagnostics market is segmented into transplant diagnostic instrument, transplant diagnostic software, transplant diagnostic reagent.

Technology

  • PCR-Based Molecular Assays
  • Sequencing-Based Molecular Assays

On the basis of technology, the Europe transplant diagnostics market is segmented into PCR-based molecular assays, and sequencing-based molecular assays.

Transplant Type

On the basis of transplant type, the Europe transplant diagnostics market is segmented into solid organ transplantation, stem cell transplantation, soft tissue transplantation, bone marrow transplantation, and other transplants.

Application

  • Diagnostic Applications
  • Research Applications

On the basis of application, the Europe transplant diagnostics market is segmented into diagnostic applications and research applications.

End User

  • Research Laboratories and Academic Institutes
  • Hospitals and Transplant Centers
  • Commercial Service Providers
  • Others

On the basis of end user, the Europe transplant diagnostics market is segmented into research laboratories and academic institutes, hospitals and transplant centers, commercial service providers, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

Transplant Diagnostics Market

On the basis of distribution channel, the Europe transplant diagnostics market is segmented into direct tender, retail sales, and others.

Europe Transplant Diagnostics Market Regional Analysis/Insights

Europe transplant diagnostics market is analyzed, and market size information is provided by country, product type, technology, transplant type, application, end user, and distribution channel.

Some countries covered in the Europe transplant diagnostics market are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and the rest of Europe.

Germany is expected to dominate the Europe transplant diagnostics market due to the rise in transplant diagnostic surgeries, increasing demand from emerging markets, and expansion of healthcare industries.

The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the market's current and future trends. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Transplant Diagnostics Market Share Analysis

The Europe transplant diagnostics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus on the Europe transplant diagnostics market.

Some of the major players operating in the Europe transplant diagnostics market are Hologic, Inc., Biofortuna Limited, Takara Bio Inc., BAG Diagnostics GmbH, Abbott, Diagnóstica Longwood SL, Adaptive Biotechnologies, NanoString, Arquer Diagnostics Ltd, CLONIT srl, Biotype GmbH, PathoNostics, altona Diagnostics GmbH, ELITechGroup, DiaSorin S.p.A., Horiba Ltd, Laboratory Corporation of America Holdings., Randox Laboratories Ltd., TransMedics, Thermo Fisher Scientific Inc., Stryker, Bio-Rad Laboratories, Inc., Zimmer Biomet, QIAGEN, F. Hoffmann-La Roche Ltd, BIOMÉRIEUX, CareDx Inc., Illumina, Inc., Luminex Corporation (A subsidiary of DiaSorin Company), IMMUCOR, among others.

Research Methodology: Europe Transplant Diagnostics Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include a Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.


SKU-
Why Choose Us


Frequently Asked Questions

The Europe Transplant Diagnostics Market is projected to grow at a CAGR of 6.2% during the forecast period by 2029.
The future market value of the Europe Transplant Diagnostics Market is expected to reach USD 2,933.94 million by 2029.
The major players in the Europe Transplant Diagnostics Market are Hologic, Inc., Biofortuna Limited, Takara Bio Inc., BAG Diagnostics GmbH, Abbott, Diagnóstica Longwood SL, Adaptive Biotechnologies, NanoString, Arquer Diagnostics Ltd, CLONIT srl, Biotype GmbH, PathoNostics, altona Diagnostics GmbH, etc.
The countries covered in the Europe Transplant Diagnostics Market are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and the rest of Europe.